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Human prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen. In prostate carcinomas, the cellular PAcP is decreased. We investigated its functional role in these cells. Several lines
of evidence support the hypothesis that cellular PAcP
functions as a neutral protein-tyrosine phosphatase and
is involved in regulating prostate cell growth. In this
study, we identify its in vivo substrate. Our results demonstrated that, in different human prostate cancer cell
lines, the phosphotyrosine (Tyr(P)) level of a 185-kDa
phosphoprotein (pp185) inversely correlates with the
cellular activity of PAcP. On SDS-PAGE, this pp185 comigrates with the c-ErbB-2 oncoprotein. Immunodepletion experiments revealed that c-ErbB-2 protein is the
major pp185 in cells. Results from subclones of LNCaP
cells indicated the lower the cellular PAcP activity, the
higher the Tyr(P) levels of c-ErbB-2. This inverse correlation was further observed in PAcP cDNA-transfected
cells. In clone 33 LNCaP cells, L-(1)-tartrate suppresses
the cellular PAcP activity and causes an elevated Tyr(P)
level of c-ErbB-2 protein. Epidermal growth factor stimulates the proliferation of LNCaP cells, which concurs
with a decreased cellular PAcP activity as well as an
increased Tyr(P) level of c-ErbB-2. Biochemically, PAcP
dephosphorylates c-ErbB-2 at pH 7.0. The results thus
suggest that cellular PAcP down-regulates prostate cell
growth by dephosphorylating Tyr(P) on c-ErbB-2 oncoprotein in those cells.

Protein tyrosine phosphorylation and dephosphorylation
play a key role in regulating the proliferation and differentiation of normal and tumor cells (1, 2). In cells, the tyrosine
phosphorylation status is apparently regulated by a dynamic
equilibrium of protein-tyrosine kinases and PTPases1 (3, 4). In
human cancers, an increased level of tyrosine phosphorylation

* This work was supported in part by National Cancer Institute, NIH,
Grant CA 72274 and Nebraska Cancer and Smoking Disease Research
Program Grant LB 506, 98 –29. The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
§ A recipient of the Graduate Student Fellowship Award from the
Graduate Studies Program, University of Nebraska Medical Center.
** To whom all correspondence and reprint requests should be addressed: Dept. of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, 600 S. 42nd St., Omaha,
NE 68198-4525. Tel.: 402-559-6658; Fax: 402-559-6650; E-mail: mlin@
mail.unmc.edu.
1
The abbreviations used are: PTPase, protein tyrosine phosphatase;
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is implicated in a high cellular proliferation rate and an eventual development of tumors (5). This effect of increased tyrosine
phosphorylation could be due to activation of protein-tyrosine
kinases, inactivation of PTPases, or both.
The biological function of PTPases in antagonizing proteintyrosine kinase activity and cellular transformation has been
demonstrated in cell culture models (for a review, see Ref. 6).
For example, protein-tyrosine phosphatase 1B and LAR PTPase dephosphorylated the IR on tyrosine residues, resulting in
a decreased tyrosine kinase specific activity of IR (7, 8). Additionally, SHP-1, an Src homology 2 domain-containing PTPase,
could be recruited by an erythropoietin receptor and subsequently down-regulated JAK2 through a dephosphorylation
mechanism (9, 10). Furthermore, by cDNA transfection, the
expression of an exogenous protein-tyrosine phosphatase 1B
suppressed the malignant transformation of NIH3T3 cells induced by the c-erbB-2 oncogene (11). Similarly, an induced
expression of DEP-1, a PTPase, inhibited cell growth by 5–10fold in human breast cancer cell line MCF-7, which is c-erbB2-amplified (12). In a xenograft animal model, c-erbB-2 genetransformed 18-Hn1 human breast carcinoma cells developed
tumors in athymic nude mice. Following LAR transfection, the
tumor growth was significantly inhibited (13). Thus, PTPases
could counteract the growth-stimulating and oncogenic activity
of protein-tyrosine kinases.
Human PAcP is a prostate epithelium-specific differentiation antigen. Two forms of PAcP have been identified: one stays
intracellular, while the other is secreted (14). Its cellular enzyme activity and mRNA level is decreased in prostate carcinomas, compared with normal or benign prostate hypertrophy
cells (15, 16). Results from many studies have demonstrated
that the cellular form of PAcP could function as a PTPase in
cells. Briefly, PAcP exhibits endogenous PTPase activity and
dephosphorylates tyrosine-phosphorylated proteins (17, 18).
Biochemically, the tyrosine phosphorylation level and the tyrosine kinase-specific activity of EGFR could be down-regulated by PAcP at a neutral pH (19). Expression of an exogenous
PAcP via either cDNA transfection (20, 21) or protein incorporation (22, 23) was associated with decreased Tyr(P) levels of
cellular proteins. Additionally, crystallographic analyses and
titration experiments revealed that PAcP could indeed function
as a “cysteine”-mediated PTPase (24, 25). Taken collectively,
these data indicate that the cellular form of PAcP is involved in
regulating tyrosine phosphorylation in prostate epithelia.
Although previous investigations suggested that PAcP acts
as a negative regulator of tyrosine phosphorylation signals, the
in vivo substrate of PAcP was not identified yet. In this study,
we analyzed protein tyrosine phosphorylation in several prosCMV, cytomegalovirus; pp185, a phosphoprotein with a molecular mass
of 185 kDa.
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tate cancer cells that express different levels of cellular PAcP.
Our results demonstrated that the Tyr(P) level of pp185, a
185-kDa phosphoprotein, negatively correlates with the cellular activity of PAcP. We clarified the identity of pp185 to be the
c-ErbB-2 oncoprotein. Furthermore, using PAcP cDNA transfection, we elucidated the relationship between PAcP expression and the Tyr(P) level of c-ErbB-2 in prostate cancer cells.
Thus, our data suggest that c-ErbB-2 protein is an in vivo
substrate of cellular PAcP.
EXPERIMENTAL PROCEDURES

Materials—FBS, RPMI 1640 culture medium, gentamicin, EGF, and
horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgGs
were purchased from Life Technologies, Inc. Charcoal/dextran-treated,
certified FBS (lot AGD6463, testosterone # 3.0 ng/dl) was from Hyclone
(Logan, UT). Protein molecular weight standard marker, acrylamide,
and a protein assay kit were obtained from Bio-Rad. Polyclonal antiErbB-2 Abs (C-18 and K-15) for immunoblotting, monoclonal antiErbB-2 Ab (9G6) for immunoprecipitation, and normal mouse IgG were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit anti-PAcP antiserum was obtained as described previously (26).
Monoclonal anti-Tyr(P) antibody (4G10) was from Upstate Biotechnology Inc. (Lake Placid, NY). Purified PAcP was isolated from human
seminal fluid as described (27). An enhanced chemiluminescence (ECL)
detection system was purchased from Amersham Pharmacia Biotech.
All other reagents were from Sigma.
Cell Culture—Human prostate carcinoma cell lines LNCaP, DU 145,
and PC-3 were obtained from the American Type Culture Collection
(Rockville, MD) and routinely maintained in RPMI 1640 medium supplemented with 5% FBS, 1% glutamine, and 0.5% gentamicin. Cells
were split once per week, defined as one passage. LNCaP cells that had
passage numbers less than 33 were designated as clone 33, greater than
80 as clone 81, and between 34 and 80 as clone 51 (28). Since cellular
PAcP activity is regulated by androgen in prostate cells (20, 29), a
steroid-reduced medium, i.e. RPMI 1640 medium containing 5% charcoal-treated, heat-inactivated FBS, was used in this study (26, 28). For
doubling time determination, after 72 h of culture, one set of attached
cells was harvested and counted, defined as cell number on day 0. The
remaining cells were fed with fresh medium and then counted on days
3, 5, and 7. Fresh medium (3 ml/well in six-well plates) was added to the
remaining cultures on days 3 and 5. To quantify cell growth, attached
cells were trypsinized and combined with the suspended cells, and the
total cell number was counted using a Coulter Counter Z1 model.
PAcP cDNA Transfectants—PC-411, -412, and -416 cells were subclones of PC-3 parental cells transfected with a full-length human PAcP
cDNA driven by a pCMV-neo expression vector, as described previously
(20). Clone 81 LNCaP cells were also transfected with the same expression vector containing human PAcP cDNA. Two subclones designated
as LNCaP-28 and -40 were obtained as the stable transfectants after
neomycin selection. LNCaP-CMV-13 is a subline of clone 81 LNCaP
cells transfected with the pCMV-neo vector alone.
Acid Phosphatase Activity Assay—p-Nitrophenol phosphate was utilized as the substrate to quantify the acid phosphatase activity at pH
5.5 by measuring the absorbency of released PNP at 410 nm (30). Since
L-(1)-tartrate is a classic inhibitor of PAcP and since greater than 90%
of L-(1)-tartrate-sensitive acid phosphatase in LNCaP cells can be
precipitated by anti-PAcP antiserum, the L-(1)-tartrate-sensitive acid
phosphatase activity was used to represent the PAcP activity (30).
Immunoprecipitation and Immunoblotting—Subconfluent cells were
harvested by scraping, pelleted, and rinsed with ice-cold 20 mM Hepesbuffered saline, pH 7.0, and then lysed in ice-cold cell lysis buffer
containing protease and phosphatase inhibitors (i.e. 20 mM Hepes, pH
7.0, 0.5% deoxycholic acid, 0.15 M NaCl, 0.1% SDS, 1% Nonidet P-40, 4
mM EDTA, 10 mM NaF, 0.1 mM ZnCl2, 10 mM Na4P2O7, 2 mM sodium
orthovanadate, 2 mM phenylmethylsulfonyl flouride, 1 trypsin-inhibitory unit of aprotinin, 4 mM leupeptin, and 1 mM pepstatin A). The
lysates were spun at 1,600 3 g for 10 min at 4 °C. The supernatants
were transferred, and protein concentration was determined using a
Bio-Rad protein assay kit. For immunoprecipitation, 1 mg of supernatant protein was incubated with 9G6 anti-ErbB-2 Ab-conjugated protein A-Sepharose complex for 2 h at 4 °C. The immunocomplexes were
spun at 700 3 g for 5 min, washed four times with ice-cold lysis buffer,
and suspended in SDS-PAGE sample buffer. For immunoblotting, an
aliquot of total lysate protein (50 mg) or the supernatant of immunoprecipitated complexes in SDS-PAGE sample buffer was electrophoresed and transferred to a nitrocellulose filter (Micron Separation Inc.,
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MA). Filters were incubated with appropriate antibodies, and the protein bands were visualized by the ECL detection system (28). For
rehybridization, the filters were stripped by a stripping buffer, i.e. 62.5
mM Tris-HCl, pH 6.7, containing 100 mM 2-mercaptoethanol and 2%
SDS, for 30 min at 50 °C. After two washes with TBST buffer (i.e. 20 mM
Tris-buffered saline, pH 7.5, containing 0.1% Tween 20), the filters were
reacted with specific Abs, and the signal was detected by the ECL
method.
RESULTS

PAcP Expression and Tyrosine Phosphorylation of pp185 in
Different Prostate Cancer Cells—Previous studies demonstrated that cellular PAcP could function as a neutral PTPase
in prostate cancer cells (19, 22, 23). To understand its biological
role, we investigated its in vivo substrate. We initially examined PAcP expression in different subclones of LNCaP cells as
well as PC-3 and DU 145 cells. As shown in Fig. 1A, PAcP
protein level in clone 33 LNCaP cells was higher than that in
clone 51 and 81 cells, while PC-3 and DU 145 cells did not
express a detectable PAcP protein. To examine the relationship
between PAcP expression and protein tyrosine phosphorylation, the same membrane was rehybridized with anti-Tyr(P)
Ab. As shown in Fig. 1B, among different subclones of LNCaP
cells, the tyrosine phosphorylation level of a protein with a
molecular mass of approximately 185 kDa (pp185) inversely
correlates with the cellular level of PAcP. Significantly, levels
of pp185 tyrosine phosphorylation were high in PC-3 and DU
145 cells (Fig. 1B), which lack PAcP expression (Fig. 1A).
To further explore the correlation between the Tyr(P) level of
pp185 and the cellular PAcP activity, we performed PAcP
cDNA transfection experiments utilizing clone 81 LNCaP cells,
which express a low level of PAcP. Two stable transfectants
were established and designated as LNCaP-28 and LNCaP-40.
Immunoblotting analyses demonstrated that PAcP expression
was increased in these two transfectants, higher than that in
clone 81 parental cells (Fig. 2A, top). The effect of exogenous
PAcP expression on protein tyrosine phosphorylation was examined with anti-Tyr(P) Ab via Western blotting. As shown in
Fig. 2A (bottom), in both LNCaP-28 and -40 cells, the Tyr(P)
level of pp185 conspicuously decreased, as compared with that
in control clone 81 parental cells. We also investigated if an
inverse correlation exists between PAcP expression and the
Tyr(P) level of pp185 in PAcP cDNA-transfected PC-3 cells.
Immunoblotting results showed that three transfectants (i.e.
PC-411, PC-412, and PC-416) expressed an exogenous PAcP
(Fig. 2B, top panel) with a decreased Tyr(P) level of pp185,
lower than that in the control parental cells (Fig. 2B, bottom).
These data indicated that although there are other phosphoproteins with altered Tyr(P) levels, the pp185 is the only one
that exhibits a diminished Tyr(P) level in all PAcP-expressing
cells.
Since c-ErbB-2 has a molecular mass of 185 kDa and is one
of the major tyrosine kinases in prostate epithelial cells (31),
we examined whether pp185 might be the c-ErbB-2 protein.
Hybridization of the same membranes shown in Fig. 1B, and
Fig. 2, A and B, with anti-ErbB-2 Ab revealed that c-ErbB-2
protein comigrates with pp185 on SDS-PAGE (data not shown).
Furthermore, in all of these cell systems analyzed, although
the tyrosine phosphorylation status was altered, there was no
significant change in the protein expression level of c-ErbB-2,
independent of its tyrosine phosphorylation status (data not
shown). Apparently the differences in Tyr(P) levels of c-ErbB-2
in different subcloned cells are not due to differences in its
protein expression.
Immunodepletion of pp185 by Anti-ErbB-2 Ab—To examine
if c-ErbB-2 is the major phosphoprotein at 185 kDa, c-ErbB-2
was immunodepleted from total lysates of clone 81 LNCaP
cells. As shown in Fig. 3A, the immunoprecipitated amounts of
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FIG. 1. Endogenous PAcP expression and tyrosine phosphorylation of
pp185. Subconfluent PC-3, DU 145, and
different subclones of LNCaP cells were
harvested, lysed, and aliquoted for immunoblotting experiments. Total cell lysates
(50 mg) were electrophoresed on a 7.5%
SDS-PAGE and transferred to a nitrocellulose filter. A, immunoblotting with rabbit anti-PAcP antiserum. B, tyrosine
phosphorylation level of total cell proteins. The filter shown in A was stripped
and then rehybridized with anti-Tyr(P)
(a-p-tyr) Ab. The arrow indicates the
pp185. PC, PC-3 cells; DU, DU 145 cells;
LNCaP C-33, C-51, and C-81, LNCaP
clone 33, clone 51, and clone 81 cells, respectively. IB, immunoblotting.

c-ErbB-2 protein increased following the dosage of Ab. The
immunodepleted cell lysates were then immunoblotted with
anti-Tyr(P) Ab. In these depleted lysates, the tyrosine phosphorylation level of pp185 decreased, proportionally to the increase
of Ab dosage (Fig. 3B). Greater than 80% of the Tyr(P) level of
the pp185 was depleted from 1 mg of cell lysate by 10 mg of Ab
(Fig. 3B). However, normal mouse IgG had no effect on immunoprecipitating c-ErbB-2 protein (Fig. 3A) and did not affect
the Tyr(P) level of pp185 (Fig. 3B). The same membrane was
subsequently reacted with anti-ErbB-2 Ab. A diminished
amount of c-ErbB-2 protein in immunodepleted lysates corresponded to the decreased tyrosine phosphorylation level of
pp185 (Fig. 3, C versus B). Thus, c-ErbB-2 protein is the major
pp185 whose Tyr(P) level inversely correlates with the cellular
PAcP activity in prostate cancer cells.
Tyrosine Phosphorylation of c-ErbB-2 in Different Prostate
Cancer Cells—To investigate whether c-ErbB-2 could be a substrate of cellular PAcP, we first examined the Tyr(P) level of
c-ErbB-2 in subclones of LNCaP cells. The c-ErbB-2 protein
was immunoprecipitated, and its tyrosine phosphorylation
level was analyzed by immunoblotting with anti-Tyr(P) Ab.
The results demonstrated the lower the cellular PAcP activity,
the higher the Tyr(P) level of c-ErbB-2 protein in LNCaP cells
(top of Fig. 4A versus Fig. 1A). The same membrane was reacted with anti-ErbB-2 Ab after stripping. As shown in the
bottom of Fig. 4A, there was no significant change in c-ErbB-2
protein levels among clone 33, 51, and 81 LNCaP cells. The
relative Tyr(P) level of c-ErbB-2 protein was semiquantified by
normalizing to its protein level after densitometric analyses. In
clone 81 cells, the tyrosine phosphorylation of c-ErbB-2 was
approximately 5-fold higher than that in clone 33 cells, while
the PAcP activity was 5-fold lower (Table I).
To evaluate the effect of exogenous PAcP on the tyrosine
phosphorylation of c-ErbB-2, we performed similar analyses
using PAcP cDNA-transfected LNCaP-28 and -40 cells. As
shown in Fig. 4B (top), in both LNCaP-28 and LNCaP-40 cells,

the tyrosine phosphorylation of c-ErbB-2 was lower than that
in clone 81 LNCaP parental cells as well as CMV vector control
cells. The same membrane was subsequently incubated with
anti-ErbB-2 Ab. The immunoblotting result revealed that cErbB-2 protein levels were essentially the same among all cells
examined (bottom of Fig. 4B). Densitometric analyses indicated
that an elevated expression of PAcP by cDNA transfection in
clone 81 LNCaP cells correlated with a decrease of the Tyr(P)
level of c-ErbB-2 by up to 65% (Table I).
We further examined tyrosine phosphorylation levels on cErbB-2 in PC-3 transfectants. Similarly, this exogenous expression of PAcP resulted in a diminished Tyr(P) level of cErbB-2 in all three transfected clones (Fig. 4C, top), while the
protein levels of c-ErbB-2 were apparently the same in all cells
(Fig. 4C, bottom). Densitometric analyses demonstrated an up
to 70% decrease in tyrosine phosphorylation of c-ErbB-2 in
PAcP cDNA transfectants, as compared with that in PC-3
parental cells (Table I).
L-(1)-Tartrate Effect on Tyrosine Phosphorylation of c-ErbB2—Since results from PAcP cDNA transfection studies revealed that an additional PAcP expression correlates with a
decreased Tyr(P) level on c-ErbB-2 protein in prostate cancer
cells, we investigated this relationship further by treating clone
33 LNCaP cells with L-(1)-tartrate, a classic inhibitor of PAcP
(23, 30). Cells were exposed to different doses of L-(1)-tartrate,
and c-ErbB-2 protein was immunoprecipitated and followed by
immunoblotted for analyzing tyrosine phosphorylation status.
As shown in Fig. 5A, the tyrosine phosphorylation level of
c-ErbB-2 increased following an increase of inhibitor concentrations. However, the c-ErbB-2 protein expression levels were
very similar among the cells exposed to different doses of L-(1)tartrate (Fig. 5B). The relative Tyr(P) level of c-ErbB-2 in cells
exposed to 5 mM L-(1)-tartrate was approximately 4.5-fold of
that in control cells (Fig. 5B). Conversely, the cellular PAcP
activity was decreased by around 20% (data not shown), as we
reported previously (22, 23). Thus, an inhibition of PAcP activ-
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FIG. 2. Exogenous PAcP expression
and tyrosine phosphorylation of
pp185. Subconfluent cells were harvested
for immunoblotting experiments. A, PAcP
expression and Tyr(P) (p-tyr) level of
pp185 in PAcP cDNA-transfected clone 81
LNCaP cells. Top, PAcP level in 50 mg of
total cell lysates. Immunoblotting was
performed with rabbit anti-PAcP antiserum. Bottom, tyrosine phosphorylation
of total cell proteins. The filter shown at
the top was stripped and rehybridized
with anti-Tyr(P) Ab. B, PAcP expression
and Tyr(P) level of pp185 in PAcP cDNA
transfected PC-3 cells. Top, PAcP level in
50 mg of total cell lysates. Bottom, tyrosine phosphorylation of total cell proteins.
Set-I and Set-II, two sets of independent
experiments. Arrows, the positions of
pp185. IB, immunoblotting.

ity concurs with an increase of tyrosine phosphorylation of
c-ErbB-2 in prostate cancer cells.
EGF Effect on Cell Growth, PAcP Activity, and Tyrosine
Phosphorylation of c-ErbB-2—EGF stimulates the growth of
LNCaP cells (20) and prostate primary cells (32). Since cellular
PAcP is possibly involved in down-regulating the growth of
prostate cells, we also analyzed whether a stimulation of cell
growth by EGF correlates with a decrease of PAcP activity in
clone 33 LNCaP cells. EGF caused an increase in cell growth
indicated by total cellular protein amounts with the optimal
dose at 10 ng/ml (Fig. 6A). In contrast, the enzyme activity of
cellular PAcP diminished following the dosage of EGF (Fig.
6A). The EGF effect in regulating tyrosine phosphorylation
status of c-ErbB-2 in these cells was further examined. Results
shown in Fig. 6B (top) demonstrated that the Tyr(P) level of
c-ErbB-2 increased, in proportion to the EGF concentrations

with the optimal induction at 10 ng/ml. The c-ErbB-2 protein
level was also inspected and shown in Fig. 6B (bottom). Densitometric analyses demonstrated an over 3-fold induction of
tyrosine phosphorylation of c-ErbB-2 by 10 ng/ml of EGF, in
comparison with that in the control group (Fig. 6B). These data
therefore indicate that EGF down-regulates cellular PAcP activity, thus resulting in the elevation of Tyr(P) level on cErbB-2 protein, which leads to an increased cell proliferation
rate.
Dephosphorylation of c-ErbB-2 by PAcP in Vitro—To elucidate a direct interaction between these two proteins, we analyzed the dephosphorylation of c-ErbB-2 by PAcP at a neutral
pH in vitro. c-ErbB-2 protein was immunoprecipitated from
clone 81 LNCaP cells. The immunocomplexes were resuspended in Hepes-buffered saline, and purified PAcP was added.
The remaining tyrosine phosphorylation level of c-ErbB-2 was
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FIG. 3. Tyrosine phosphorylation of
pp185 in c-ErbB-2-depleted cell lysates. An aliquot of 1 mg of total cell
lysates from clone 81 LNCaP cells was
incubated with various amounts of antiErbB-2 Ab or 10 mg of normal mouse IgG
(IgG) as indicated in the figure for 1 h.
Immunocomplexes were spun for experiments shown in panel A, and supernatants were collected for experiments
shown in panels B and C, respectively. A,
immunoblotting of immunoprecipitated
proteins from 1 mg of cell lysate with antiErbB-2 Ab. B, tyrosine phosphorylation of
pp185 in the immunodepleted cell lysates.
50 mg of cell lysates from the supernatant
of each immunoprecipitated sample were
electrophoresed and transferred to a nitrocellulose filter. Immunoblotting was
performed with anti-Tyr(P) (a-p-tyr) Ab.
Arrow, the position of pp185. C, c-ErbB-2
protein levels remained in the immunodepleted cell lysates. The same filter shown
in B was rehybridized with anti-ErbB-2
Ab. IP, immunoprecipitation; IB, immunoblotting; ID, immunodepletion.

examined by immunoblotting with anti-Tyr(P) Ab. As shown in
Fig. 7A, PAcP dephosphorylated c-ErbB-2 protein on tyrosine
residues following a time course. c-ErbB-2 protein amounts in
each sample were analyzed by immunoblotting with antiErbB-2 Ab (Fig. 7B). The relative tyrosine phosphorylation
level of c-ErbB-2 was semiquantified. The results indicated
that PAcP dephosphorylated c-ErbB-2 protein in a time-dependent fashion (Fig. 7C). However, in the presence of a PTPase inhibitor, sodium orthovanadate, no dephosphorylation of
c-ErbB-2 by PAcP was observed (Fig. 7C). As a negative control, there was no dephosphorylation in the absence of PAcP
protein (Fig. 7C).
The Relationship among the Growth Rate, PAcP Expression,
and Phosphotyrosine Level of c-ErbB-2 in Prostate Cancer
Cells—Our data indicate that tyrosine phosphorylation levels
of c-ErbB-2 can be regulated by cellular PAcP in human prostate cancer cells. Since c-ErbB-2 is one of the major proteintyrosine kinases involved in growth factor-stimulated proliferation of mammalian cells including prostate cells (32, 33), we
investigated the biological significance of decreased tyrosine
phosphorylation of c-ErbB-2 protein by analyzing the cell proliferation rate. We first examined the growth rate of different
LNCaP subcloned cells. As shown in Table I, the doubling time
of clone 33, 51, and 81 cells in a steroid-reduced medium was
approximately 112, 57, and 49 h, respectively. Similar studies

indicated that growth rates of PAcP cDNA-transfected LNCaP
subcloned cells (LNCaP-28 and -40) and cDNA-transfected
PC-3 subcloned cells (PC-412 and -416) were lower than that of
their parental control cells (Table I). The cellular PAcP activity
in each cell type was further measured. Data taken collectively
show that in all three independent prostate cancer cell systems, the higher the activity of cellular PAcP is, the lower the
tyrosine phosphorylation levels of c-ErbB-2 and the slower the
cell growth rates (Table I).
DISCUSSION

The protein-tyrosine phosphatase activity of PAcP has been
demonstrated in many biochemical studies over the last decade
(17–19, 22–25, 28). In normal canine prostate glands, well
differentiated epithelia expressed a high level of PAcP and a
low level of tyrosine-phosphorylated proteins (34). In contrast,
poorly differentiated canine prostate basal cells did not express
a detectable PAcP, while the Tyr(P) level was high (34). Treatment of canine differentiated prostate tissue with orthovanadate resulted in an increase in cellular Tyr(P) level and a
decrease in PAcP activity (35). Additionally, in human prostate
cancer cell cultures, the tyrosine phosphorylation of cellular
proteins inversely correlated with cellular PAcP activity (20,
23). These studies imply that PAcP is involved in regulating
protein tyrosine phosphorylation in differentiated prostate ep-
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TABLE I
The cell growth rate, cellular PAcP activity, and c-ErbB-2
phosphorylation level in different prostate cancer cells
Cell lines and subclones

LNCaP
Clone 33
Clone 51
Clone 81
PAcP cDNA-transfected LNCaP
Clone 81
PAcP-28
PAcP-40
CMV-13
PAcP cDNA-transfected PC-3
PC-3
PC-411
PC-412
PC-416

Doubling
timea

PAcP activityb

Tyr(P) level of
c-ErbB-2c

h

A410/mg/min

-fold

111.7
56.8
48.8

0.636 6 0.019 1.00
0.197 6 0.007 2.47
0.118 6 0.001 5.03

51.7
86.5
90.3
NDe

0.141 6 0.002
0.872 6 0.002
0.514 6 0.013
0.193 6 0.004

1.00 (2.85)d
0.39 (1.11)
0.35 (1.00)
1.14 (3.26)

32.2
ND
49.2
53.5

0
0.181 6 0.008
0.139 6 0.001
0.223 6 0.007

1.00 (3.03)
0.52 (1.57)
0.67 (2.03)
0.33 (1.00)

a
For doubling time determination, cells were seeded at a density of
5 3 104 cells/well in a steroid-reduced medium in six-well plates. The
cell counting method was described under “Experimental Procedures.”
The data shown indicated the average of duplicate wells, and similar
results were observed in two sets of independent experiments.
b
PAcP activity assay was performed as described under “Experimental Procedures.” The results represent the L-(1)-tartrate-sensitive AcP
activity. The data shown are the average of two sets of independent
experiments.
c
The relative level of Tyr(P) on c-ErbB-2 was semiquantified by
normalizing to its protein level after densitometric analyses from the
data shown in Fig. 4.
d
The data indicate the relative Tyr(P) level of c-ErbB-2 by designating the lowest point as 1.0 in each cell system.
e
ND, not determined.

FIG. 4. Effect of PAcP expression on tyrosine phosphorylation
of c-ErbB-2 in prostate cancer cells. An aliquot of 1 mg of total cell
lysates from each cell line was incubated with 5 mg of anti-ErbB-2 Ab for
2 h at 4 °C. The immunocomplexes were washed, and immunoprecipitated proteins were electrophoresed on a 7.5% SDS-gel. Immunoblotting
was performed with anti-Tyr(P) (a-p-tyr) Ab followed by anti-ErbB-2 Ab.
Tyrosine phosphorylation and protein levels of c-ErbB-2 in different subcloned LNCaP cells (A), PAcP cDNA-transfected clone-81 LNCaP cells
(B), and PAcP cDNA-transfected PC-3 cells (C) were shown. LNCaPCMV cells, a subclone of LNCaP clone 81 cells transfected with the
vector alone. Set-I and Set-II in C represent two sets of independent
experiments. IP, immunoprecipitation; IB, immunoblotting.

ithelia. Nevertheless, the in vivo substrate(s) of PAcP has not
yet been identified.
In the current study, our results clearly indicate that the
tyrosine phosphorylation status of c-ErbB-2 protein is regulated by PAcP in prostate cancer cells. For example, our initial
experiments using clone 81 LNCaP and PC-3 cells lacking
PAcP expression demonstrated a poor immunoprecipitation of
c-ErbB-2 by an Ab (C-18) against its C terminus, but not by an
Ab (9G6) recognizing its N terminus (data not shown). Perhaps
the inaccessibility of C-18 Ab is due to the high extent of
tyrosine phosphorylation on C terminus of c-ErbB-2 protein in
these two cell lines. Among different subclones of LNCaP cells,
loss of PAcP expression correlated with an elevation of Tyr(P)
level on c-ErbB-2 (Figs. 1 and 4). PAcP cDNA transfection in
clone-81 LNCaP and PC-3 cells concurred with a diminished
tyrosine phosphorylation of c-ErbB-2 (Figs. 2 and 4). When
clone 33 LNCaP cells were exposed to a PAcP inhibitor, L-(1)tartrate, a significant induction of tyrosine phosphorylation on
c-ErbB-2 protein was observed (Fig. 5). Furthermore, EGF
treatment on the same cells caused a decrease in cellular PAcP

FIG. 5. Effect of L-(1)-tartrate on tyrosine phosphorylation of
c-ErbB-2. Subconfluent clone 33 LNCaP cells were exposed to 0, 2.5,
and 5.0 mM of L-(1)-tartrate, respectively, for 16 h. An aliquot of 1 mg
of total cell lysates was reacted with 5 mg of anti-ErbB-2 Ab for 2 h at
4 °C. Immunocomplexes were washed, and proteins were electrophoresed on a 7.5% SDS-gel. A, immunoblotting of immunoprecipitated cErbB-2 proteins with anti-Tyr(P) (a-p-tyr) Ab. B, immunoblotting of the
same filter with anti-ErbB-2 Ab after stripping. The ratio indicates the
relative Tyr(P) level of c-ErbB-2 protein after densitometric analyses.
IP, immunoprecipitation; IB, immunoblotting.

activity, with a parallel increase in Tyr(P) level of c-ErbB-2
(Fig. 6). Biochemically, PAcP dephosphorylated c-ErbB-2 on
tyrosine residues in a time-dependent fashion (Fig. 7). To the
best of our knowledge, this is the first demonstration of a
putative in vivo substrate of PAcP, a differentiation-associated
PTPase.
The inverse correlation is exhibited between cellular PAcP
expression and the Tyr(P) level of c-ErbB-2 as well as cell
growth rate in different LNCaP subcloned cells and PAcP
cDNA-transfected PC-3 cells (Table I). However, compared
with LNCaP-40 subcloned cells, LNCaP-28 cells express a
higher level of PAcP (Fig. 2A and Table I), while the tyrosine
phosphorylation level of c-ErbB-2 as well as the cell growth
rate in these two cell lines are very similar (Fig. 4B and Table
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FIG. 6. Effect of EGF on cell growth, cellular PAP activity, and
tyrosine phosphorylation of c-ErbB-2. Subconfluent LNCaP clone
33 cells were fed with medium containing 1% charcoal-treated FBS for
24 h before exposed to 0, 1, 10, and 100 ng/ml of EGF, respectively, for
16 h. Cells then were harvested, aliquoted, and lysed by the lysis buffer
with orthovanadate (for immunoprecipitation) or without orthovanadate (for PAcP activity assay). PAcP activity assay was performed as
described under “Experimental Procedures.” An aliquot of 1 mg of total
cell lysates was reacted with 5 mg of anti-ErbB-2 Ab for 2 h at 4 °C, and
immunoprecipitated proteins were electrophoresed on a 7.5% SDS-gel.
A, cellular PAcP activity and total protein amount (mg/T75 flask) of
cells exposed to different doses of EGF. Bar, the range of results from
two sets of samples. B, immunoblotting of c-ErbB-2 in immunocomplexes with anti-Tyr(P) (a-p-tyr) Ab (top), or with anti-ErbB-2 Ab (bottom). The relative level of Tyr(P) on c-ErbB-2 was semiquantified by
normalizing to its protein level after densitometric analyses. IP, immunoprecipitation; IB, immunoblotting.

I). To address this question, we analyzed the PAcP level in their
conditioned media, since there are two forms of PAcP (14, 20).
The results indicated that LNCaP-28 cells secreted a significantly higher amount of PAcP than LNCaP-40 cells (A410 5
0.209 of LNCaP-28 versus 0.002 of LNCaP-40). Thus, we proposed that a fraction of PAcP in LNCaP-28 cells is directed to
the constitutively secretory pathways. Therefore, the high
PAcP level in total cell lysates of LNCaP-28 cells includes the
intermediate form of secretory PAcP, as described in our previous studies (20). Alternatively, the inhibition of the Tyr(P)
level of c-ErbB-2 may reach to the optimum by the exogenous
PAcP in LNCaP-40 cells. Although LNCaP-28 cells produce
increased amounts of PAcP, the excess PAcP cannot function to
further dephosphorylate c-ErbB-2 in vivo.
c-ErbB-2 is a transmembrane glycoprotein of Mr 185,000
that has an extensive sequence homology to EGFR (36, 37).
Similar to EGFR, c-ErbB-2 is a putative growth factor receptor
with an intrinsic tyrosine kinase activity, yet its ligand has not
been identified (38). Amplification or overexpression of the

FIG. 7. Tyrosine phosphorylation level of PAcP-treated
c-ErbB-2. c-ErbB-2 protein was immunoprecipitated from 1 mg of clone
81 LNCaP cell lysates and washed thoroughly to remove sodium orthovanadate in the lysis buffer. Immunocomplexes were then incubated
with purified PAcP (3 mg/sample) in the presence or absence of 200 mM
sodium orthovanadate at room temperature for 10, 20, and 30 min. In
control experiments, immunocomplexes were incubated with Hepesbuffered saline alone. Tyrosine phosphorylation (A) and protein levels
(B) of c-ErbB-2 after incubation with PAcP are shown. OV, sodium
orthovanadate; IP, immunoprecipitation; IB, immunoblotting. C, the
summary of densitometric analyses of Tyr(P) (p-tyr) level on c-ErbB-2.
Tyrosine phosphorylation level of each sample (A) was normalized to its
corresponding protein level (B). The ratio of the sample in the absence of
PAcP without sodium orthovanadate at 0 min was defined as 1.0. Similar
results were obtained from three sets of independent experiments.

c-erbB-2 gene has been found in approximately 20 –30% of
human breast cancers (39). Patients with breast tumors overexpressing the c-erbB-2 gene have a significantly lower survival rate and a shorter time to relapse than patients with
tumors lacking overexpression of the c-erbB-2 gene (39). In
prostate cancer, however, studies on the role of c-ErbB-2 have
yielded conflicting results (40 – 43). Therefore, c-ErbB-2 has not
been accepted as a marker for prostate tumor progression (44,
45). In the present study, we utilized a variety of prostate
cancer subcloned cells as model systems to investigate not only
the interaction between PAcP and c-ErbB-2, but also a possible
functional role of c-ErbB-2 in regulating the growth of prostate
cancer cells. Our results clearly demonstrate that the tyrosine
phosphorylation level of c-ErbB-2 correlates with the proliferation rate of prostate cancer cells (for a summary, see Table I).
Since cellular PAcP activity in prostate carcinomas is lower
than that in noncancerous prostate cells (15, 16),2 we hypothesize that cells with a low level of PAcP have an unregulated
2

J. Andresson, P. S. Rao, and M. F. Lin, unpublished data.
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tyrosine phosphorylation on c-ErbB-2, which eventually leads
to the uncontrolled proliferation of cancers.
Several lines of evidence indicate that PTPases interact with
protein-tyrosine kinases intracellularly and regulate kinase
signal transduction pathways. For example, a physical association between LAR and IR was shown by coimmunoprecipitation from Chinese hamster ovary cells, which overexpressed
the human IR gene (8). When rat fibroblast cells with an
overexpression of the human IR gene were transfected with
protein-tyrosine phosphatase 1B cDNA, insulin- and insulinlike growth factor I-stimulated signalings were inhibited (9).
Subsequently, it was found that protein-tyrosine phosphatase
1B was coprecipitated with the IR b-subunit by specific Abs
from insulin-stimulated cells (46). SHP-1, an Src homology 2
domain-containing PTPase, bound selectively to the tyrosinephosphorylated erythropoietin receptor through its Src homology 2 domain and henceforth inactivated JAK2 by dephosphorylation (9, 10). Thus, a physical association indeed exists
between PTPases and their in vivo substrates. In previous
studies, we observed that the majority of cellular PAcP resides
in the cytosol and that a fraction of it could associate with the
plasma membrane using immunofluorescent staining with a
confocal microscopy (21).3 It indicated that cellular PAcP and
c-ErbB-2 are localized favorably for interaction. However, we
have had limited success in demonstrating a physical interaction between PAcP and c-ErbB-2 by coimmunoprecipitation
techniques. Several plausible reasons could explain this phenomenon. For example, since there is no significant sequence
homology between PAcP and other members of the PTPase
family (47, 48), the interaction mechanism of PAcP with its in
vivo substrate(s) could be different from other PTPases. Alternatively, it is possible that the association between PAcP and
c-ErbB-2 is very labile and that the binding is highly sensitive
to the experimental conditions. Thus, the dissociation between
these two proteins occurs during experimental procedures.
Crystallographic results clearly demonstrated that PAcP has
two critical free sulfhydryl groups at cysteine residues that
could serve as phosphate acceptors (24). Subsequently, titration experiments revealed a “S-32P” intermediate product of
PAcP occurring during the dephosphorylation reaction (25).
Thus, substrate-trapping mutants generated by site-directed
mutagenesis of these cysteine residues should provide us with
new tools for studying in vivo association between PAcP and
c-ErbB-2.
The treatment of LNCaP cells with L-(1)-tartrate and EGF
resulted in an increased tyrosine phosphorylation level of cErbB-2 protein. Since L-(1)-tartrate is a classic inhibitor of
PAcP and also since its inhibition effect on cellular PAcP in
LNCaP cells has been illustrated (22, 23), we propose that the
induction of the Tyr(P) level of c-ErbB-2 by L-(1)-tartrate is
directly due to the suppression of cellular PAcP activity. However, the molecular mechanism of EGF effect on tyrosine phosphorylation of c-ErbB-2 is not completely understood. It is
possible that the suppression of cellular PAcP activity by EGF
leads to a hyperphosphorylated c-ErbB-2. Other possibilities
also exist. For example, we observed a coimmunoprecipitation
of c-ErbB-2 protein by anti-EGFR Ab in clone 33 LNCaP cells
(data not shown), indicating that a heterodimerization occurs
between these two receptors. Since EGF treatment stimulates
the tyrosine kinase-specific activity of EGFR, the increase of
Tyr(P) level of c-ErbB-2 is possible via a cross-phosphorylation
mechanism (49). Furthermore, the PAcP activity could be suppressed by direct phosphorylation through the active EGFR
because of favorable subcellular localization, or by shutdown of

3

M. F. Lin, M. L. Chen, and J. K. Christman, unpublished data.

22103

its in vivo synthesis machinery. Detailed investigations are
needed to delineate the molecular mechanism of interaction
between cellular PAcP and c-ErbB-2 in LNCaP cells.
In conclusion, our data clearly demonstrated that cellular
PAcP can dephosphorylate c-ErbB-2 oncoprotein on tyrosine
residues in prostate cancer cells. This dephosphorylation results in a diminished proliferation rate of these cells. Further
studies will help to elucidate their in vivo interactions and
molecular sites of dephosphorylation of c-ErbB-2 by PAcP.
These results will aid in understanding the mechanism of one
step in multistage prostate carcinogenesis.
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